Wipzo Healthcare Private LimitedLucknow, India
Gastro Care Professional information

RABWIP-LS

Prescription acid-control and prokinetic combination

Composition Rabeprazole 20 mg + Levosulpiride 75 mg SR Capsules · Wipzo Healthcare Private Limited

RABWIP-LS combines rabeprazole with sustained-release levosulpiride for clinician-selected management of upper-gastrointestinal symptoms.

Wipzo portfolioCapsules
RABWIP-LS Capsules product presentation
BrandRABWIP-LS
Rx
Use responsiblyFollow approved literature and professional advice
i
Need complete product information?Request the approved pack literature or connect with our product-information team.
Contact Wipzo
01
Start here

Product introduction

Rabeprazole reduces stomach-acid secretion. Levosulpiride is a dopamine-receptor antagonist with prokinetic effects used in some markets for selected dyspeptic and motility-related symptoms.

The combination should have a defined indication and review period. Persistent or alarm symptoms require investigation rather than repeated empirical use.

Important contextThis page explains the composition and general ingredient context. The approved local product label remains the authority for indication, dose, contraindications and monitoring.
02
Clinical context

Uses of RABWIP-LS

  • Clinician-directed treatment of selected reflux/dyspeptic symptom patterns when both acid suppression and a prokinetic component are considered appropriate.
  • Not a universal treatment for every episode of gas, pain, nausea or acidity.
  • Use should be reassessed if symptoms persist, recur frequently or are accompanied by alarm features.

Benefits and product context

01

Acid suppression

Rabeprazole blocks the final step in gastric-acid secretion.

02

Motility support

Levosulpiride has dopamine-antagonist effects that can influence upper-gastrointestinal movement.

03

Combined regimen

One sustained-release capsule contains both clinician-selected components.

03
Know what to watch for

Side effects and warning signs

Possible effects include headache, abdominal discomfort, diarrhoea or constipation, dizziness, sleepiness and hormone-related effects.

!New tremor, stiffness, restlessness or involuntary movement
!Breast discharge, menstrual changes or sexual-function changes
!Fainting, palpitations or severe dizziness
!Persistent diarrhoea, allergic swelling or breathing difficulty
When to seek helpNew movement symptoms, fainting, severe allergy, vomiting blood or black stools need prompt medical assessment.
Administration

How to use RABWIP-LS

Swallow the sustained-release capsule whole and follow the prescribed timing, often before food when specified by the approved label. Do not crush, chew or open it. Do not continue beyond the review date or restart it from an old prescription without clinician approval.

Mechanism

How it works

Rabeprazole is activated in gastric parietal cells and inhibits the H+/K+-ATPase proton pump. Levosulpiride blocks dopamine D2 receptors and can enhance gastrointestinal motility, but dopamine blockade can also produce neurological and prolactin-related adverse effects.

04
Use with care

Safety advice

01

Pregnancy

Avoid unless essential

The combination requires explicit prescriber assessment during pregnancy.

02

Breastfeeding

Consult your doctor

Levosulpiride can affect prolactin and suitability while breastfeeding requires review.

03

Driving

May impair driving

Drowsiness, dizziness or movement effects can occur. Do not drive if affected.

04

Kidney health

Dose review

Levosulpiride elimination may be affected by kidney impairment.

05

Liver health

Medical review

Review liver disease and the appropriateness of ongoing acid-suppressive therapy.

Practical checklist

Quick tips

Small steps that support safer, more informed use.

  • Swallow the SR capsule whole.
  • Report tremor, stiffness, restlessness or unusual movements.
  • Do not ignore weight loss, difficulty swallowing, bleeding or persistent vomiting.
  • Review prolonged proton-pump-inhibitor use with the clinician.
  • Share all psychiatric, heart-rhythm and digestive medicines.
05
At a glance

Product fact box

Product categoryPrescription medicine
Therapy areaGastro Care
Dosage formSustained-release capsule
Habit formingNo known habit-forming potential
CompanyWipzo Healthcare Private Limited
Information statusProfessional reference
06
Medicine review

Interactions and combinations

Give your prescriber or pharmacist a complete list of prescription medicines, over-the-counter products, vitamins, herbals and supplements.

Review

Antipsychotic and dopamine-active medicines

Effects can overlap or oppose one another and increase neurological or hormonal adverse effects.

Review

Sedatives and alcohol

These may worsen drowsiness or impaired coordination.

Review

Methotrexate and pH-dependent medicines

Rabeprazole can interact with selected medicines through acid suppression or altered exposure.

07
Common questions

Frequently asked questions

Is RABWIP-LS the same as rabeprazole alone?+

No. It also contains sustained-release levosulpiride, which changes the indications, precautions and side-effect profile.

Can I open the capsule?+

Sustained-release products should generally be swallowed whole unless the approved leaflet says otherwise.

Why are movement symptoms important?+

Levosulpiride blocks dopamine receptors and can rarely cause clinically important movement-related effects.

Can I use it every time I have acidity?+

No. Recurrent symptoms need diagnosis and a reviewed treatment plan.

Ingredient-information references

General ingredient context was reviewed against authoritative health or regulatory resources. These links are not a substitute for the approved Wipzo product label.

Medical information notice

This page is intended for product and professional information. It does not replace diagnosis, a prescription, a treatment plan, approved product literature or advice from a qualified healthcare professional.

Contact Wipzo →